Clinical Trial Update: A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia [Phase 4]

View source ↗

Summary

Pfizer's Phase 4 trial of Inotuzumab Ozogamicin in Chinese patients with relapsed or refractory acute lymphoblastic leukemia has completed and results have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Inotuzumab ozogamicin (inotuzumab ozogamicin)

Snippet

Sponsor: Pfizer | Conditions: Acute Lymphoblastic Leukemia | Phase 4 | Status: COMPLETED | Results posted: 2025-08-07